Back to results
US 2020/0206170 A1Published application
Solid Solution Compositions and Use in Chronic Inflammation
AssigneeInfirst Healthcare Limited
InventorsRobin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
Life of this patent
Estimating the term…
Abstract
The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
Claims25
A solid solution pharmaceutical composition comprising:
- a) one or more propionic acid derived non-steroidal anti-inflammatory drugs (NSAIDs) in a concentration of about 100 mg/mL to about 750 mg/mL;
- b) one or more pharmaceutically-acceptable hard fats comprising one or more glycerolipids, the one or more pharmaceutically-acceptable hard fats in an amount of at least 30% by weight of the pharmaceutical composition;
- c) one or more pharmaceutically-acceptable liquid lipids comprising a mixture of one or more partially hydrolyzed fats, the one or more pharmaceutically-acceptable liquid lipids in an amount of less than 45% by weight of the pharmaceutical composition, and
- wherein the solid solution pharmaceutical composition is not a multi-phasic composition.
1 more element
The solid solution pharmaceutical composition according to claim 16, wherein the one or more monoglycerides is glycerol monolinoleate.
Dependencies are inferred from the claim text.